Coherus Unveils Exciting Phase 1/2 Clinical Results for Casdozokitug: A Revolutionary IL-27 Targeted Antibody, Showcased at the 2023 ESMO Immuno-Oncology Congress!
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Therapy Introduction Recently, Coherus BioSciences announced the presentation of Phase 1/2 clinical data on Casdozokitug, a novel IL-27-targeted therapy. The data showed promising results, with two out of nine squamous NSCLC patients experiencing confirmed partial responses when treated with Casdozokitug in combination with an…